Skip to main content
Log In
submission complete icon
Submit
envelope
E-Alerts
cart
Cart
OpenAthens/Shibboleth »
Enter words / phrases / DOI / ISBN / authors / keywords / etc.
Search in:
Search This Journal
Search ASCO Journals
Advanced Search
Menu
Newest Content
Issues
Current Issue
Past Issues
Special Content
JCO 40th Anniversary
ASCO Guidelines
Special Series
JCO Podcasts
Cancer Stories Podcast
Meeting Abstracts
Oncology Grand Rounds
Understanding the Pathway
Authors
Author Center
Open Access Terms
Preparing a Manuscript
Determine My Article Type
Format My Manuscript
Submit My Manuscript
Contact Editorial
What To Expect
Peer Review Process
My Article Was Accepted
Policies and Guidelines
Journal Policies
Embargo Policy
Author Promotion Toolkit
Resources
From the Editors
Author FAQ
Professional English and Academic Editing Support
Submit to JCO
Subscribers
Subscriber Center
Manage Subscription
Renew Subscription
View/Change User Info
Institutions and Librarians
Subscribe to this Journal
Email Alerts
Subscriber FAQ
About
About JCO
Editorial Roster
Permissions
Reprints
Advertising
Become a Reviewer
Contact Us
ASCO Publications
Journal of Clinical Oncology
JCO Oncology Practice
JCO Global Oncology
JCO Clinical Cancer Informatics
JCO Precision Oncology
ASCO Publications Home
Careers
Career Center
ASCO Career Fair
Follow @JCO_ASCO on Twitter
Log In
Vol. 22, No. 15, August 1, 2004
Editorials
Epidermal Growth Factor Receptor and Epidermal Growth Factor Receptor Therapies in Renal Cell Carcinoma: Do We Need a Better Mouse Trap?
Dancey
pp. 2975
–
2977
Citation
|
Full Text
|
PDF (59 KB)
Substitution of Oral Fluoropyrimidines for Infusional Fluorouracil With Radiotherapy: How Much Data Do We Need?
Crane et al.
pp. 2978
–
2981
Citation
|
Full Text
|
PDF (66 KB)
The Limits of Limited Stage Lymphoma
Miller
pp. 2982
–
2984
Citation
|
Full Text
|
PDF (62 KB)
Comments and Controversies
Developing a System to Assess the Quality of Cancer Care: ASCO's National Initiative on Cancer Care Quality
Schneider et al.
pp. 2985
–
2991
Citation
|
Full Text
|
PDF (88 KB)
Related Content
Errata
Erratum
Understanding Cancer Treatment and Outcomes: The Cancer Care Outcomes Research and Surveillance Consortium
Ayanian et al.
pp. 2992
–
2996
Citation
|
Full Text
|
PDF (159 KB)
Related Content
Erratum
ERRATUM
Managing Accrual in Cooperative Group Clinical Trials
Demmy et al.
pp. 2997
–
3002
Citation
|
Full Text
|
PDF (770 KB)
ORIGINAL REPORTS
Genitourinary Cancer
Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer
Rowinsky et al.
pp. 3003
–
3015
Abstract
|
Full Text
|
PDF (991 KB)
Gastrointestinal Cancer
Preoperative Uracil, Tegafur, and Concomitant Radiotherapy in Operable Rectal Cancer: A Phase II Multicenter Study With 3 Years' Follow-Up
Fernández-Martos et al.
pp. 3016
–
3022
Abstract
|
Full Text
|
PDF (201 KB)
Gastrointestinal Cancer
A Randomized Trial Comparing Defined-Duration With Continuous Irinotecan Until Disease Progression in Fluoropyrimidine and Thymidylate Synthase Inhibitor—Resistant Advanced Colorectal Cancer
Lal et al.
pp. 3023
–
3031
Abstract
|
Full Text
|
PDF (200 KB)
Hematologic Malignancies
Chemotherapy With or Without Radiotherapy in Limited-Stage Diffuse Aggressive Non-Hodgkin's Lymphoma: Eastern Cooperative Oncology Group Study 1484
Horning et al.
pp. 3032
–
3038
Abstract
|
Full Text
|
PDF (285 KB)
Hematologic Malignancies
Ongoing Monoclonal B-Cell Proliferation Is Not Common in Gastric B-Cell Lymphoma After Combined Radiochemotherapy
Alpen et al.
pp. 3039
–
3045
Abstract
|
Full Text
|
PDF (259 KB)
Hematologic Malignancies
Utility of Fine-Needle Aspiration As a Diagnostic Technique in Lymphoma
Hehn et al.
pp. 3046
–
3052
Abstract
|
Full Text
|
PDF (86 KB)
Head and Neck Cancer
Phase II Study of Neoadjuvant Carboplatin and Paclitaxel Followed by Radiotherapy and Concurrent Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: Therapeutic Monitoring With Plasma Epstein-Barr Virus DNA
Chan et al.
pp. 3053
–
3060
Abstract
|
Full Text
|
PDF (177 KB)
Head and Neck Cancer
Cisplatin, Fluorouracil, and Leucovorin Induction Chemotherapy Followed by Concurrent Cisplatin Chemoradiotherapy for Organ Preservation and Cure in Patients With Advanced Head and Neck Cancer: Long-Term Follow-Up
Psyrri et al.
pp. 3061
–
3069
Abstract
|
Full Text
|
PDF (242 KB)
Breast Cancer
Long-Term Cardiac Follow-Up in Relapse-Free Patients After Six Courses of Fluorouracil, Epirubicin, and Cyclophosphamide, With Either 50 or 100 mg of Epirubicin, As Adjuvant Therapy for Node-Positive Breast Cancer: French Adjuvant Study Group
Bonneterre et al.
pp. 3070
–
3079
Abstract
|
Full Text
|
PDF (111 KB)
Breast Cancer
Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Tan et al.
pp. 3080
–
3090
Abstract
|
Full Text
|
PDF (726 KB)
Breast Cancer
Patient-Physician Concordance: Preferences, Perceptions, and Factors Influencing the Breast Cancer Surgical Decision
Janz et al.
pp. 3091
–
3098
Abstract
|
Full Text
|
PDF (100 KB)
Epidemiology
Differential Prognostic Impact of Comorbidity
Read et al.
pp. 3099
–
3103
Abstract
|
Full Text
|
PDF (150 KB)
Epidemiology
High Levels of Circulating Insulin-Like Growth Factor-I Increase Prostate Cancer Risk: A Prospective Study in a Population-Based Nonscreened Cohort
Stattin et al.
pp. 3104
–
3112
Abstract
|
Full Text
|
PDF (103 KB)
Gynecologic Cancer
Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
Moore et al.
pp. 3113
–
3119
Abstract
|
Full Text
|
PDF (233 KB)
Gynecologic Cancer
Duration of Response to Second-Line, Platinum-Based Chemotherapy for Ovarian Cancer: Implications for Patient Management and Clinical Trial Design
Markman et al.
pp. 3120
–
3125
Abstract
|
Full Text
|
PDF (83 KB)
Gynecologic Cancer
Her-2/
neu
Overexpression and Amplification in Uterine Papillary Serous Carcinoma
Slomovitz et al.
pp. 3126
–
3132
Abstract
|
Full Text
|
PDF (137 KB)
Neurooncology
Temozolomide As Initial Treatment for Adults With Low-Grade Oligodendrogliomas or Oligoastrocytomas and Correlation With Chromosome 1p Deletions
Hoang-Xuan et al.
pp. 3133
–
3138
Abstract
|
Full Text
|
PDF (264 KB)
Pediatric Oncology
Cardiovascular Status in Long-Term Survivors of Hodgkin's Disease Treated With Chest Radiotherapy
Adams et al.
pp. 3139
–
3148
Abstract
|
Full Text
|
PDF (116 KB)
Pediatric Oncology
Using Health-Related Quality of Life Measures to Predict Cardiac Function in Survivors Exposed to Anthracyclines
Ginsberg et al.
pp. 3149
–
3155
Abstract
|
Full Text
|
PDF (93 KB)
Pediatric Oncology
Preliminary Results From a Phase II Trial of Conformal Radiation Therapy and Evaluation of Radiation-Related CNS Effects for Pediatric Patients With Localized Ependymoma
Merchant et al.
pp. 3156
–
3162
Abstract
|
Full Text
|
PDF (235 KB)
Supportive Care and Quality of Life
Long-Term Silicone Central Venous Catheters Impregnated With Minocycline and Rifampin Decrease Rates of Catheter-Related Bloodstream Infection in Cancer Patients: A Prospective Randomized Clinical Trial
Hanna et al.
pp. 3163
–
3171
Abstract
|
Full Text
|
PDF (187 KB)
Supportive Care and Quality of Life
Assessing Quality of Life During Chemotherapy for Pleural Mesothelioma: Feasibility, Validity, and Results of Using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module
Nowak et al.
pp. 3172
–
3180
Abstract
|
Full Text
|
PDF (641 KB)
Review Article
Review of Determinants of Patients’ Preferences for Adjuvant Therapy in Cancer
Jansen et al.
pp. 3181
–
3190
Abstract
|
Full Text
|
PDF (107 KB)
Diagnosis in Oncology
Uncommon Manifestations of Common Malignancies
Soto Parra et al.
pp. 3191
–
3192
Citation
|
Full Text
|
PDF (610 KB)
Uncommon Manifestations of Common Malignancies
Devi et al.
pp. 3192
–
3193
Citation
|
Full Text
|
PDF (208 KB)
Uncommon Manifestations of Common Malignancies
Naing et al.
pp. 3194
–
3195
Citation
|
Full Text
|
PDF (211 KB)
Art of Oncology
Reassurance
Steensma
pp. 3196
–
3198
Citation
|
Full Text
|
PDF (51 KB)
Correspondence
Phase III Study of Letrozole Versus Tamoxifen As First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group
Buzdar
pp. 3199
–
3200
Citation
|
Full Text
|
PDF (66 KB)
In Reply:
Mouridsen et al.
pp. 3200
–
3201
Citation
|
Full Text
|
PDF (61 KB)
Free Circulating DNA: Good As a Diagnostic Marker in Lung Cancer?
Altundag et al.
pp. 3201
–
3202
Citation
|
Full Text
|
PDF (61 KB)
In Reply:
Pastorino et al.
p. 3202
Citation
|
Full Text
|
PDF (61 KB)
Oxaliplatin Toxicity Masquerading As Recurrent Colon Cancer
Tisman et al.
pp. 3202
–
3204
Citation
|
Full Text
|
PDF (61 KB)
Errata
ERRATUM
p. 3205
Citation
|
Full Text
|
PDF (18 KB)
ERRATUM
p. 3205
Citation
|
Full Text
|
PDF (18 KB)
Related Content
Pediatric Oncology
Efficacy of Topotecan and Cyclophosphamide Given in a Phase II Window Trial in Children With Newly Diagnosed Metastatic Rhabdomyosarcoma: A Children’s Oncology Group Study
JCO
RSS Feed
(What is RSS?)
Most Read
Most Cited
Alcohol and Cancer: A Statement of the American Society of Clinical Oncology
LoConte et al.
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
Schneider et al.
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
Hoimes et al.
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in
BRCA1
and/or
BRCA2
in the PROfound Trial
Mateo et al.
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
Loprinzi et al.
View More »
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Marabelle et al.
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Le et al.
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sehn et al.
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Johnston et al.
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
Schneider et al.
View More »
